Auszug
Die Antiarrhythmikaverordnungen sind 2006 in ihrem Gesamtvolumen praktisch unverändert geblieben und scheinen sich auf einem niedrigen Niveau zu. stabilisieren. Die Dominanz von Amiodaron (Klasse III) und Flecainid (Klasse Ic) hat weiter zugenommen.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. (1991): Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 324: 781–788.
Farre J, Romero J, Rubio JM, Ayala R, Castro-Dorticos J (1999): Amiodarone and “primary” prevention of sudden death: critical review of a decade of clinical trials. Am J Cardiol 83: 55D–63D.
Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G (2004): Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 25: 1385–1394.
Hocini M, Jais P, Sanders P, Takahashi Y, Rotter M, Rostock T, Hsu LF, Sacher F, Reuter S, Clementy J, Haissaguerre M (2005) Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study. Circulation 112: 3688–3696
Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH (2003) Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med 163: 777–785.
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML for the Multicenter Automatic Defibrillator Implantation Trial II Investigators (2002): Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 346: 877–883.
Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M, Hatala R, Opolski G, Müller HW, Meinertz T; SOPAT Investigators (2004) Suppression of paroxysmal atrial tachyarrhythmias—results of the SOPAT trial. Eur Heart J 25: 1395–1404.
Sanders GD, Hlatky MA, Owens DK (2005): Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 353: 1471–1480.
Vaughan Williams EM (1975): Classification of antidysrhythmic drugs. Pharmac Ther B 1: 115–138.
Waldo AL, Camm AJ, deRuyter H, et al. for the SWORD Investigators (1996): Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 348: 7–12.
Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators (2002): A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347: 1825–1833.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Eschenhagen, T. (2008). Antiarrhythmika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-540-72548-0_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-72547-3
Online ISBN: 978-3-540-72548-0
eBook Packages: Medicine (German Language)